Iveric Bio (Formerly Ophthotech)
A science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD9.1b (Public information from Apr 2023)
Princeton New Jersey (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 210m | 210m | 210m | 4.0m | 210m | 210m |
| % growth | - | - | - | - | (98 %) | 5149 % | - |
| EBITDA | - | 111m | (65.2m) | (61.1m) | (88.6m) | (115m) | (190m) |
| % EBITDA margin | - | 53 % | (31 %) | (29 %) | (2215 %) | (55 %) | (90 %) |
| Profit | - | 114m | 63.1m | (58.9m) | (84.5m) | (115m) | (185m) |
| % profit margin | - | 54 % | 30 % | (28 %) | (2114 %) | (55 %) | (88 %) |
| R&D budget | 152m | 66.3m | 41.7m | 39.6m | 62.8m | 85.1m | 117m |
| R&D % of revenue | - | 32 % | 20 % | 19 % | 1570 % | 41 % | 56 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$36.0m | Series A | ||
$30.0m | Series B | ||
N/A | - | ||
$50.0m | Growth Equity VC | ||
| N/A | N/A | IPO | |
$41.7m | Post IPO Equity | ||
* | N/A | $50.0m | Post IPO Equity |
N/A | Post IPO Equity | ||
* | N/A | $100m | Post IPO Equity |
* | $250m | Post IPO Debt | |
* | N/A | $300m | Post IPO Equity |
* | $5.9b Valuation: $5.9b 28.1x EV/LTM Revenues -31.1x EV/LTM EBITDA | Acquisition | |
| Total Funding | AUD179m | ||
Related Content
Recent News about Iveric Bio (Formerly Ophthotech)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.